On the recordJuly 19, 2011
It is not very useful to investors to have the reams of data about Sarbanes-Oxley for a firm that has no revenue yet.
Source
congress.govEditor's note · Context
Toomey argues that Sarbanes-Oxley data is irrelevant for pre-revenue biotech firms.
Share
More from Pat Toomey
Aug 1, 2022
Government actions that raise my costs ultimately impact my residents and my ability to provide affordable housing.
Dec 13, 2022
It is absolutely essential to investigate any fraud and violations of existing law, and prosecute those who are committing those crimes.
Jul 30, 2022
It's a budgetary gimmick that has the intent of making it possible to have a huge explosion in unrelated spending. This is not what this bill was about. We can fix it. We can do it immediately.
Aug 1, 2022
We should avoid the temptation to adopt new so-called tenant protections or permanent rental assistance that will have negative unintended consequences.
Other voices in this conversation
